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Abstract
Fibroblast growth factor-2 (FGF2) has been demonstrated to be a promising osteogenic factor for treating osteoporosis. Our
earlier study shows that transplantation of mouse Sca-1
+ hematopoietic stem/progenitor cells that are engineered to
express a modified FGF2 leads to considerable endosteal/trabecular bone formation, but it also induces adverse effects like
hypocalemia and osteomalacia. Here we report that the use of an erythroid specific promoter, b-globin, leads to a 5-fold
decrease in the ratio of serum FGF2 to the FGF2 expression in the marrow cavity when compared to the use of a ubiquitous
promoter spleen focus-forming virus (SFFV). The confined FGF2 expression promotes considerable trabeculae bone
formation in endosteum and does not yield anemia and osteomalacia. The avoidance of anemia in the mice that received
Sca1
+ cells transduced with FGF2 driven by the b-globin promoter is likely due to attenuation of high-level serum FGF2-
mediated stem cell mobilization observed in the SFFV-FGF2 animals. The prevention of osteomalacia is associated with
substantially reduced serum Fgf23/hypophosphatemia, and less pronounced secondary hyperparathyroidism. Our
improved stem cell gene therapy strategy represents one step closer to FGF2-based clinical therapy for systemic skeletal
augmentation.
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Introduction
Osteoporosis, or porous bones, is a disease that leads to an
increased risk of fracture. Over 20 million people have osteopo-
rosis in the United States, and approximately 1.3 million people
each year suffer a bone fracture as a result of osteoporosis. Current
therapies and drugs in development range from bisphosphonates,
parathyroid hormone (PTH), RANKL inhibitors or anti-sclerostin
antibodies. However, these therapies cause significant side effects
after long-term use [1,2,3]. Therefore, the development of
alternative strategies for efficient treatment of osteoporosis is
warranted.
Previous studies have demonstrated that fibroblast growth
factor-2 (FGF2; also known as basic FGF or bFGF) is a bone
anabolic agent able to promote bone formation by stimulating
proliferation and differentiation of mesenchymal stem cells [4,5,6].
Systemic administration of recombinant FGF2 protein increases
bone formation [7,8,9,10] and promotes fracture repair [11].
FGF2 primarily initiates the growth of new trabeculae and
increases trabecular mass and interconnectivity [7,12]. However,
due to a very short in vivo half-life of FGF2, daily injection of large
quantities of FGF2 protein is necessary, which is infeasible and
expensive in clinical practice. As such, we have taken a
hematopoietic stem cell (HSC) gene therapy approach to achieve
long-term stable FGF2 expression. After transplantation of mouse
bone marrow (BM) Sca-1
+ hematopoietic stem/progenitor cells
that were transduced with a murine leukemia virus (MLV)-based
vector expressing a modified FGF2 gene, we observed substantially
enhanced trabecular bone formation at the endosteal surface [13].
The osteogenesis-promoting capacity of FGF2 after transplanta-
tion of FGF2-expressing HSCs is superior to other similar
osteogenic factors such as bone morphogenic protein 4 (BMP4)
[14]. However, the MLV-based HSC gene therapy yields FGF2
levels that are ,100-fold higher than physiological concentrations
in serum, which may increase chances of unintended side-effects,
including tumorigenesis. In addition, we also observed an up to a
100-fold variation in FGF2 serum levels in different mice, which is
likely due to silencing of the viral long terminal repeat (LTR) and/
or clonal effects. Moreover, mice with high-level serum FGF2
developed anemia and osteomalacia [13].
To overcome the limitations of the current therapy and further
develop FGF2-based HSC gene therapy into a new strategy for
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37569treating severe osteoporosis, we hypothesized that the use of an
erythroid promoter to drive the expression of FGF2 might increase
local expression at the marrow cavity and decrease the serum
FGF2 levels. If this is the case, the confined FGF2 expression to
the marrow cavity would promote endosteal bone formation while
minimize adverse effects associated with high-level serum FGF2.
We choose a b-globin promoter because 1) human HB , a specific
gene encoding the beta chain of hemoglobin in erythroid cells, is
strongly activated during the terminal stages of erythrocyte
development [15]; 2) niches for erythropoiesis have been identified
only in adult BM, and erythropoiesis is not spatially restricted to
the areas proximal to sinusoids but occurs over the entire marrow
space [16]; and 3) the b-globin promoter has been successfully
used in stem cell gene therapy for treating red blood cell (RBC)
diseases [17,18]. In this study, we tested whether the use of the b-
globin promoter can confine FGF2 expression to the marrow,
thereby eliminating the adverse effects of high-level serum FGF2.
Results
FGF2 driven by the b-globin promoter confines FGF2
expression to the marrow cavity
In a previous study, we used MLV, a gammaretroviral vector, to
express FGF2 [13]. Here we used a lentiviral vector (Lenti) to
express transgene, because self-inactivating lentiviral vectors are
less genotoxic than gammaretroviral vectors due to their
differential preference for integration [19,20]. To achieve high-
level transgene expression in hematopoietic cells, we used a spleen
focus-forming virus (SFFV) promoter as a ubiquitous promoter to
drive FGF2 expression [21]. To confine transgene expression to
the marrow, we used an erythroid lineage-specific promoter, b-
globin (Fig. 1a). As a negative control, a green fluorescent protein
(GFP)-expressing vector was used in our study (Fig. 1a).
We first tested the specificity of the b-globin promoter. Sca-1
+
cells purified by magnetic cell sorting (MACS) were transduced
with Lenti b-globin-FGF2 and transplanted into lethally irradiated
C57BL/6 mice. Six weeks after transplantation, BM cells were
harvested and separated into 2 populations: Ter119
+ erythroid
cells and Ter119
2 cells. Enzyme-linked immunosorbent assay
(ELISA) analysis of extracted cellular proteins showed that FGF2
expression in Ter119
+ erythroid cells was more than 100-fold
higher than in control Ter119
2 cells (Fig. 1b). This result
demonstrates that the use of the b-globin promoter can achieve
highly specific expression of the transgene in BM erythroid cells.
Of interest, Ter119
+ cells in the spleen expressed FGF2 at 20–50
fold lower levels compared to BM Ter119
+ cells and FGF2 was
undetectable in mature red blood cells (not shown).
We further tested the hypothesis that erythroid cell-mediated
FGF2 expression allows for the confining of FGF2 to the marrow
because BM is the only identified niche for erythropoiesis. For this
purpose, mice were transplanted with Sca-1
+ cells that were
transduced with either Lenti b-globin-FGF2 or Lenti SFFV-FGF2.
Six weeks after transplantation, serum and BM cells were
harvested for analysis of FGF2 by ELISA. To measure the
confinement levels, we determined the relative ratio of marrow
FGF2 to serum FGF2. FGF2 expression in marrow cells was used
as a surrogate for local FGF2 levels in the marrow. As expected,
this ratio was increased by 5-fold in the b-globin-FGF2 animals
compared to the SFFV-FGF2 animals (Fig. 1c). This result
demonstrates that the b-globin promoter-mediated FGF2 expres-
sion in erythroid cells leads to a 5-fold enrichment of FGF2 in the
marrow cavity relative to serum.
Confined FGF2 expression leads to greater bone
formation than SFFV-mediated ubiquitous FGF2
expression after myeloablative HSC transplantation
In our pilot studies, we observed that ,20% of the mice could
not survive to 6 weeks after myeloablative HSC transplantation
due to side effects like severe anemia. We hypothesized that the
severe side effect in the SFFV-FGF2 group might be due to the
high-level expression of FGF2 driven by a strong ubiquitous
promoter. To test this, we diluted Lenti SFFV-FGF2 transduced
cells with untransduced Sca-1
+ cells by factors of 1, 2, 4 and 8
before transplantation. At 6–8 weeks after transplantation, we
sacrificed animals and analyzed serum FGF2 and parameters of
bone formation.
To analyze effects of different FGF2 serum concentrations on
bone formation, we grouped mice based on their serum FGF2
levels: 1) low levels (,100 pg/ml; range 11–80 pg/ml; mean
32 pg/ml), 2) medium levels (100–400 pg/ml; range 100–350 pg/
ml; mean 190 pg/ml), and 3) high levels (.400 pg/ml; range
480–800 pg/ml; mean 680 pg/ml) (Fig. 2a). By comparison,
average serum FGF2 levels in the GFP control group and the b-
globin group were 17 pg/ml (range: 0–60 pg/ml) and 34 pg/ml
(range: 1–80 pg/ml), respectively (Fig. 2a).
We conducted peripheral quantitative computed tomography
(pQCT) analysis to determine the effects of FGF2 on bone
formation. We observed a trend of decrease in cortical bone
mineral density (BMD) with the increase of serum FGF2 (Fig. 2b).
For trabecular bone formation, we observed that femurs from the
b-globin group showed a substantial increase in BMD relative to
the GFP control (P,0.001) (Fig. 2c). However, in the SFFV-
FGF2 groups, only medium-level serum FGF2 induced a
significant increase in trabecular BMD compared to the GFP
control, while no significant differences were observed in the low
and high serum GFP groups. Other bone parameters such as
trabecular content measured by pQCT also showed the same
pattern (data not shown). Of interest, there was no difference in
serum FGF2 levels between the b-globin and the low SFFV-FGF2
group, but substantial trabecular bone formation was observed in
the b-globin group (Fig. 2c). These data suggest that confined
expression of FGF2 to the marrow leads to striking increase in
trabeculae bone formation in endosteum.
We also measured the serum levels of alkaline phosphatase
(ALP), a serum biomarker of bone formation. Consistent with the
pQCT data, ALP activity at 6–8 weeks after transplantation was
increased by ,150% in the b-globin animals compared to the
GFP control (Fig. 2d). In the SFFV-FGF2 mice, an increase of
serum FGF2 from ,30 pg/ml to ,200 pg/ml significantly
increased the ALP activity, while a further increase to ,600 pg/
ml led to a drop in the ALP activity (Fig. 2d). We also examined
another serum biomarker of bone formation, osteocalcin, and saw
the same pattern as the ALP activity (data not shown). These data
further support our conclusion that b-globin promoter-mediated
confined FGF2 expression leads to substantial bone formation.
To investigate the mechanisms of confined FGF2 expression-
mediated bone formation, we extracted total RNAs from whole
femurs and conducted real-time reverse transcription polymerase
chain reaction (RT-PCR) analysis. The GFP group served as a
negative control. Consistent with the serum ALP (encoded by Alp1)
and osteocalcin (encoded by Bglap) data, RT-PCR analysis showed
that expression of Alp1 and Bglap was increased ,5 and ,7-fold,
respectively (Fig. 2e). Expression of Runx2 and Sp7 (also known as
osterix), transcription factors specifically expressed in osteoblasts,
was increased 4–6 fold in the b-globin-FGF2 group relative to
control (Fig. 2e), suggesting that FGF2 may promote osteoblast
proliferation. Similarly, we observed that confined FGF2 expres-
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which is consistent with the report that FGF2 activates BMP
signaling [22]. These data suggest that FGF2 promotes bone
formation due in part to activation of BMP signaling. In addition,
the expression of Col1a1, the gene that encodes the major
extracellular matrix protein collagen 1a type 1, was increased by
5-fold in the b-globin-FGF2 group (Fig. 2e). This observation
suggests that FGF2 also stimulates secretion of extracellular
matrix. In the SFFV-FGF2 animals, the increase in expression
of these genes was less pronounced than the b-globin-FGF2
animals (not shown).
Taken together, our data demonstrate that the b-globin
promoter mediated confined FGF2 expression to the BM cavity
substantially increases bone formation, likely by stimulating
osteoblast proliferation and secretion of osteogenic factors like
Bmp2 and Bmp4.
Confined FGF2 expression eliminates high-level FGF2
associated anemia and ameliorates extramedullary
hematopoiesis
Systemic FGF2 administration induces side effects such as
extramedullary hematopoiesis and anemia [23]. Therefore, we
hypothesized that the anemia might be induced by high-level
serum FGF. Gross examination of the animals showed that body
weight in the SFFV-FGF2 animals was lower than control in a
FGF2 concentration-dependent manner, with high-level serum
FGF2 leading to a 20% decrease at 8 weeks after transplantation
(P,0.001) (Fig. 3a). This observation is consistent with the earlier
report that FGF2 inhibits weight gain in growing animals [24]. To
investigate the effects of FGF2 on anemia, we counted RBC in
peripheral blood. Fig. 3b shows that even low-level serum FGF2
decreased RBC count by 10–15% (P,0.05), while further increase
in FGF2 led to an additional drop in the RBC count. In the high
SFFV-FGF2 group, the RBC counts were decreased by ,40%
relative to control (P,0.001), leading to severe anemia. The
observed anemia in animals with high serum FGF2 levels may
have contributed to the retarded body weight gain and sickness in
some animals. In the b-globin-FGF2 animals, the RBC counts
were also decreased to the same level as in the low SFFV-FGF2
animals (Fig. 3b). These data suggest that FGF2 plays a negative
role in erythropoiesis in a serum FGF2 dose-dependent manner,
and the b-globin promoter mediated confined FGF2 expression
decreases serum FGF2 levels and thereby prevents anemia. Of
interest, no significant difference in white blood cell counts
between all the groups was observed, while platelet counts were
significantly decreased in mice with medium- or high-level serum
FGF2 (not shown).
Figure 1. Use of the b-globin promoter confines FGF2 expression to the bone marrow. (a) Schematic of the self-inactivating (SIN) lentiviral
vector for expression of the modified human FGF2 and GFP control. D indicates the SIN design with partially deleted U3 of the 39 long terminal
repeat. cPPT, central polypurine tract; Wpre, posttranscriptional regulatory element; RRE, rev-responsive element; SFFV, spleen focus-forming virus U3
promoter; y, packaging signal; b-globin: the human b-globin promoter from 59 translated region (1.6 kb). (b) ELISA analysis of FGF2 in BM erythroid
(Ter119
+) and non-erythroid (Ter119
2) cells demonstrates the specificity of the b-globin promoter. (c) The use of b-globin promoter leads to confined
expression of FGF2 to the marrow. Serum levels and FGF2 expression were determined in marrow cells from mice that had received Sca-1
+ cells
transduced with Lenti b-globin-FGF2 or Lenti SFFV-FGF2 (n=5 mice/group). The relative ratio of FGF2 levels in serum to the marrow is presented.
doi:10.1371/journal.pone.0037569.g001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37569We and others have shown that FGF2 induces extramedullary
hematopoiesis [13]. As expected, we also observed that FGF2
serum levels were positively associated with the spleen weight
(Fig. 3c). To analyze cell subpopulations in the spleen, we minced
the spleens and analyzed cells by flow cytometry. In the high
SFFV-FGF2 group, the portion of the CD45R
+ B cells decreased
by 10-fold and the CD3
+ T cells decreased by ,3-fold, while the
Gr-1
+ or CD11b
+ myeloid cells and the Ter119
+ erythroid cells
increased by 3–5 fold relative to control (Fig. 3d). These results
are suggestive of extramedullary hematopoiesis. The decreased
percentages of B and T cells in the spleens can be explained by the
dilution effect of strikingly increased myeloid and erythroid cells in
the high SFFV-FGF2 animals. We also observed a significant
increase in percentage of LSK (Lin
2Sca1
+c-kit
+) stem cells in the
spleen of mice with high FGF2, suggesting stem cell mobilization.
By contrast, the change in the subpopulation profile was less
pronounced in the b-globin-FGF2 animals (Fig. 3d). These data
suggest that the b-globin promoter mediated confined FGF2
expression leads to less pronounced extramedullary hematopoiesis.
We speculated that FGF2-associated extramedullary hemato-
poiesis and anemia is due to stem cell dysregulation. To test this
hypothesis, we analyzed expression of genes associated with stem
cell regulation in BM cells by real-time RT-PCR. We found that
expression of Spp1, which encodes osteopontin, increased substan-
tially in an FGF2 dose-dependent manner (P,0.001) (Fig. 3e).
Given that osteopontin is a negative regulatory factor in the stem
cell niche that controls the stem cell number [25], this result
suggests that FGF2 decreases the stem cell pool in the marrow by
upregulating osteopontin. High-level FGF2 also led to an
approximately 70% decrease in Cxcr12 (also known as SDF-1)
expression (P,0.001) (Fig. 3e), which is consistent with an earlier
report that FGF2 posttranscriptionally down-regulates SDF-1
expression [26]. Because SDF-1/CXCR4 axis modulates homing,
BM retention and mobilization of HSCs, a marked decrease of
SDF-1 in the high SFFV-FGF2 group may have led to substantial
stem cell mobilization, contributing to splenomegaly (Fig. 3c). In
contrast, in the b-globin-FGF2 animals, the increase of Spp1
expression was less pronounced and no significant change in
CXCR12 was observed (Fig. 3e). These data suggest that high-
level FGF2 may decrease HSC pool by negatively regulating stem
cell niches and decrease marrow cellularity by attenuating BM
retention capacity, while confined FGF2 expression substantially
ameliorates these effects and thus prevents severe anemia.
Confined FGF2 expression eliminates high-level FGF2-
associated osteomalacia
FGF2 administration impairs bone mineralization [27] and
high-level serum FGF2 leads to osteomalacia [13]. We thus
conducted Goldner’s trichrome staining on femurs to examine
bone minerization. As expected, in the SFFV-FGF2 group, we
observed unmineralized bone and the areas of unmineralized bone
were positively associated with serum FGF2 levels (Fig. 4a). In
sharp contrast, the newly formed bone was completely mineralized
in the b-globin-FGF2 animals (Fig. 4a). These data demonstrate
that confined FGF2 expression abrogates osteomalacia that is
associated with high-level serum FGF2 levels. Of interest, even in
the low SFFV-FGF2 group, in which the same FGF2 levels were
detected as in the b-globin group, areas of unmineralized bone
were still observed (Fig. 4a).
We further investigated the mechanisms underlying complete
minerization in the b-globin-FGF2 animals but development of
osteomalacia in the SFFV-FGF2 animals. We hypothesized that
FGF23 may be a crucial factor because previous studies show that
FGF23 is a causative factor of hypophosphatemia and osteoma-
lacia [28,29] and forced FGF23 expression in osteoblasts inhibits
mineralization and promotes osteomalacia [30]. To test our
hypothesis, we first examined serum Fgf23 levels by ELISA. The
serum Fgf23 levels in the high SFFV-FGF2 animals increased
more than 13-fold (P,0.001), while Fgf23 was only slightly
increased in the b-globin-FGF2 animals (Fig. 4b). Consistent with
this result, real-time RT-PCR analysis of femurs indicated a more
than 80-fold upregulation of Fgf23 in the high SFFV-FGF2 group
(P,0.001), while the increase of Fgf23 expression in the b-globin-
FGF2 group was ,5-fold (Fig. 4b). Furthermore, regression
analysis showed a linear positive association between serum FGF2
and Fgf23 (P,0.001) (Fig. 4c). These data suggest that attenuated
Fgf23 levels in animals with confined FGF2 expression has
contributed to the abrogation of osteomalacia.
Secondary hyperparathyroidism is often associated with osteo-
malacia [31]; we thus measured serum levels of PTH. As expected,
in the high SFFV-FGF2 animals, PTH was increased by 5-fold
(P,0.001), while the increase in the b-globin-FGF2 animals was
less pronounced (P,0.01) (Fig. 4d). FGF23 regulates phosphate
homeostasis and high-level FGF23 leads to depletion of serum
phosphates [31]. As expected, in the high SFFV-FGF2 animals,
the phosphate levels were substantially lower than control
(2.8 mg/dl vs. 4.7 mg/dl; P,0.001), while only a slight decrease
of serum phosphate in the b-globin-FGF2 animals was observed
(P=0.06) (Fig. 4e). In addition, consistent with our previous
study, we also observed hypocalcaemia in high SFFV-FGF2
animals (8.560.2 mg/dl vs. 9.760.3 mg/dl for control; P,0.01)
(Fig. 4f). However, the calcium levels in the b-globin-FGF2
animals were in the normal range (9.460.2 mg/dl; P=0.40)
(Fig. 4f).
Taken together, our data suggest that high-level Fgf23,
hypophosphatemia and hypocalcaemia may have contributed to
secondary hyperparathyroidism and osteomalacia in the SFFV-
FGF2 animals, while low-level Fgf23 in the b-globin-FGF2
animals does not lead to a significant depletion of phosphate,
thereby preventing osteomalacia.
Figure 2. Confined expression of FGF2 in the marrow substantially increases bone formation. (a) Serum FGF2 levels in different groups
of animals. To analyze the FGF2 dosage effects, the SFFV-FGF2 mice were stratified into 3 groups. (b) Cortical bone mineral density (BMD) as
determined by pQCT analysis. GFP control vs. b-globin-FGF2 or low SFFV-FGF2, not significant; GFP control vs. medium SFFV-FGF2, P,0.05; GFP
control vs. high SFFV-FGF2, P,0.01. (c) Trabecular bone mineral density (BMD) as determined by pQCT analysis. GFP control vs. b-globin-FGF2,
P,0.001; GFP control vs. low SFFV-FGF2, not significant; GFP control vs. medium SFFV-FGF2, P,0.01. (d) Serum ALP activity at ,8 weeks after
transplantation. GFP control vs. b-globin-FGF2, P,0.001; GFP control vs. low SFFV-FGF2, P,0.001; GFP control vs. medium SFFV-FGF2, P,0.01; b-
globin-FGF2 vs. low SFFV-FGF2, P,0.001; b-globin-FGF2 vs. medium SFFV-FGF2, P,0.001. (e) Real-time RT-PCR analysis of osteogenesis-related genes
in the femurs. Alkaline phosphatase (Alpl), osteocalcin (Bglap), Runx2, osterix (Sp7), and collagen type Ia1( Col1a1), bone morphogenetic protein
receptor-1b (Bmpr1b), bone morphogenetic protein 2 (Bmp2), bone morphogenetic protein 4 (Bmp4), were analyzed. Data shown are presented as
mean 6 SEM (n=10 mice/group).
doi:10.1371/journal.pone.0037569.g002
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37569High-level serum FGF2 induces considerable trabecular
bone formation after nonmyeloablative HSC
transplantation but still promotes anemia and
osteomalacia
In the above studies, we observed less pronounced trabecular
bone formation and obvious animal illness in the high SFFV-
FGF2 group, which is apparently inconsistent with our previous
report in which a sublethal irradiation dosage was used [13]. We
reasoned that this might be because lethally irradiated animals are
more susceptible to high-level FGF2-associated adverse effects like
anemia, leading to severe sickness at ,6 weeks after transplan-
tation. To test our hypothesis that irradiation dosage is a crucial
factor underlying the discrepancy, we irradiated animals at 3 Gray
(Gy) before HSC transplantation. To ensure HSC engraftment in
a non-myeloablative transplantation setting, we expanded cells
with a homeobox (HOX) gene [32] after transduction of Sca-1
+
cells with Lenti SFFV-FGF2. One week after transduction, 1610
7
Sca1
+ cells were transplanted into each mouse. At 11 weeks after
transplantation, we euthanized the animals for analysis. We
observed high-level FGF2 in these animals (,600 pg/ml). While
the cortical BMD was slightly decreased in the SFFV-FGF2
animals, the trabecular BMD was markedly increased from
,150 mg/cm
3 in control animals to ,400 mg/cm
3 in high
FGF2 animals (Fig. 5a). This result is similar to the considerable
trabecular bone formation observed in the b-globin-FGF2 animals
(Fig. 2b). Godner’s trichrome staining also confirmed the effects
of high FGF2 on bone formation (Fig. 5b). However, the
overwhelming osteomalacia was still evident (Fig. 5b). In addition,
we observed overt hypophosphatemia in all the animals and
anemia in some (data not shown). Together, this study resolved the
apparent discrepancy and consolidated the conclusion that the b-
globin promoter mediated confined FGF2 expression attenuates
anemia and eliminates osteomalacia.
Discussion
Here we report that use of the b-globin promoter leads to a 5-
fold enrichment of FGF2 expression in the marrow compared to
the ubiquitous promoter SFFV-mediated transgene expression.
The confined expression of FGF2 leads to a substantial increase in
trabecular bone formation with no severe side effects like anemia
and osteomalacia that are associated with systemic administration
of FGF2. In contrast to our earlier report, the new approach leads
to considerable trabecular bone formation with only slightly
increased serum FGF2 relative to baseline levels of ,10 pg/ml.
Figure 3. Confined FGF2 expression eliminates high-level FGF2
associated anemia and ameliorates extramedullary hemato-
poiesis. (a) FGF2 negatively affects body weight. Mice were weighed at
8 weeks after transplantation. GFP control vs. b-globin-FGF2, not
significant; GFP control vs. low SFFV-FGF2, P,0.05; GFP control vs.
medium SFFV-FGF2, P,0.001; GFP control vs. high SFFV-FGF2, P,0.001.
(b) FGF2 negatively affects red blood cell count. Red blood cells in
peripheral blood were counted at 8 weeks after transplantation. GFP
control vs. b-globin-FGF2, P,0.05; GFP control vs. low SFFV-FGF2,
P,0.05; GFP control vs. medium SFFV-FGF2, P,0.01; GFP control vs.
high SFFV-FGF2, P,0.001. (c) FGF2 induces extramedullary hematopoi-
esis in a concentration-dependant manner. Shown are representative
spleens and the spleen weight in different groups. GFP control vs. b-
globin-FGF2, P,0.05; GFP control vs. low SFFV-FGF2, P,0.05; GFP
control vs. medium SFFV-FGF2, P,0.01; GFP control vs. high SFFV-FGF2,
P,0.001. (d) Flow cytometry analysis of CD45R
+ B cells, CD3
+ T cells, Gr-
1
+ and CD11b
+ myeloid cells, and Ter119
+ erythroid cells in spleens
from the GFP control mice, the b-globin-FGF2 mice and the high SFFV-
FGF2 mice at 8 weeks after transplantation. (e) Relative mRNA
expression of Spp1, and Cxcl12 in femurs from the GFP control mice,
the b-globin-FGF2 mice and the high SFFV-FGF2 mice. For Spp1, GFP
control vs. all the other groups, P,0.001. For Cxcl12, GFP control vs.
high SFFV-FGF2, P,0.001; others, GFP control vs. other groups, not
significant. Data shown are presented as mean 6 SEM (n=10 mice/
group).
doi:10.1371/journal.pone.0037569.g003
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37569Figure 4. Confined FGF2 expression abrogates high-level FGF2-associated osteomalacia. (a) Representative illustration of Goldner’s
trichrome staining of femurs from each group. Green indicates mineralized bone and red or pink unmineralized bone. (b) Serum Fgf23 levels and
relative Fgf23 mRNA expression in femurs from the GFP control mice, the b-globin-FGF2 mice and the high SFFV-FGF2 mice. P,0.001 for all
comparisons. (c) Serum Fgf23 is positively correlated with serum FGF2 levels. P,0.001. (d). Serum levels of PTH. P,0.001 for all comparisons. (e)
Serum phosphate levels. GFP control vs. b-globin-FGF2, P=0.06; P,0.001 for all the other comparisons. (f) Serum calcium levels. GFP control vs. b-
globin-FGF2, P=0.40; P,0.01 for all the other comparisons. Data shown are presented as mean 6 SEM (n=10 mice/group).
doi:10.1371/journal.pone.0037569.g004
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,30 pg/ml may also eliminate the potential untoward effects of
high-level FGF2, such as promoting tumorigenesis in concert with
other factors.
FGF2 remarkably and rapidly enhances bone formation
through its stimulatory effects on proliferation [33,34,35] and
survival [36] of osteoprogenitor cells. However, after two decades
of development, systemic FGF2 administration has not been used
in clinical therapy to enhance osteogenesis, largely due to its severe
side effects [13,27]. To minimize the adverse effects of high-level
FGF2, we proposed a new concept of confining FGF2 to the
marrow and thus promoting trabecular bone formation by using
an erythroid-specific promoter to drive FGF2 expression. Because
marrow is the only identified niche for erythropoiesis, the b-globin
promoter-mediated FGF2 expression leads to considerable
trabecular bone formation and substantially decreases serum
FGF2 to levels that are only slightly higher than physiological
concentrations. Our finding has important implications for the
safety of FGF2-based therapy. FGF2 is a pleiotropic factor that
affects the growth, differentiation, and survival of various cell
types. Its overexpression promotes tumor neovascularization and
metastasis [37] and aberrant FGF signaling is also associated with
cancer development and progression [38]. Our advance in
decreasing serum FGF2 levels by 5-fold with the use of the b-
globin promoter might largely eliminate this concern.
In addition to minimizing the safety concern of systemic FGF2
therapy, our new approach for HSC gene therapy is also safer to
use in clinical applications than previous strategies. First, self-
inactivating lentiviral vectors are apparently safer than gammar-
etroviral vectors in terms of genotoxicity and oncogenic potential,
in particular when the enhancer element is depleted from the
vector [19,20]. Second, in contrast to viral promoters, no silencing
effects of lineage-specific promoter have been observed, which
makes it easier to control the dosage of therapeutic genes. Third,
the use of lineage-specific promoter in HSC gene therapy
enhances safety [39]. Although uncontrolled activation of
growth-promoting genes in stem cells can lead to oncogenesis,
this is unlikely if vector transcriptional activity is restricted to fully
differentiated cells [18,40].
In our high SFFV-FGF2 group, we reproduced high-level
FGF2-induced adverse effects such as anemia and osteomalacia.
Our mechanistic analyses suggest that these are induced by
FGF2’s effects on hematopoiesis and phosphate homeostasis.
Earlier studies suggest that FGF2 negatively affects normal BM
hematopoiesis by several mechanisms: 1) destroys the CXCL12/
CXCR4 axis by downregulation of CXCL12, leading to stem cell
mobilization [26]; and 2) limits the size of the stem cell pool by
increasing osteopontin (Spp1) expression [25]. Our analysis of
femurs from the high SFFV-FGF2 group confirmed these findings.
FGF2-mediated decrease of stem cell pool and mobilization of
stem cells out of marrow niche result in dysfunctional marrow
hematopoiesis and compensatory extramedullary hematopoiesis.
However, even with massive (,20-fold) increase in erythroid cells
in the spleen, the inefficient erythropoiesis outside of erythroblast
islands leads to anemia. In contrast to animals with high-level
FGF2, the b-globin promoter-mediated confined FGF2 expression
substantially ameliorates the negative effects of FGF2 on
hematopoiesis, and development of overt anemia was not observed
in these animals.
The second major unintended effect of high-level FGF2 is
osteomalacia. Our data and related publications demonstrate that
FGF23 plays a pivotal role in osteomalacia-related side effects
[31,41]. FGF23 is a phosphaturic hormone that acts on the kidney
to increase phosphate excretion; high-level FGF23 results in
depletion of phosphate from the body, leading to osteomalacia.
We observed a strong correlation between Fgf23 levels and PTH
levels and unmineralized bone areas. Increased Fgf23 production
may have contributed to the development of secondary hyper-
parathyroidism [42]. An alternative explanation is that high
demand for calcium due to massive bone formation induces
hypocalcaemia, which gives rise to secondary hyperparathyroid-
ism, which induces upregulation of Fgf23 and depletion of
phosphate leading to osteomalacia. However, this inference is
not supported by our observation in the b-globin FGF2 animals, in
which considerable trabecular bone formation was observed, while
these animals manifest less severe hyperparathyroidism and
hypophosphatemia compared to high SFFV-FGF2 animals.
Therefore, our data suggest that hypocalcemia and hypophospha-
temia are a consequence rather than a cause of high-level Fgf23 in
the SFFV-FGF2 animals.
The causative link between FGF2 and Fgf23 is still missing. We
observed a strong positive correlation between serum FGF2 and
serum Fgf23, but whether FGF2 directly upregulates Fgf23 is
unknown. A recent report shows that overexpression of nuclear
high molecular weight FGF2 isoform increases FGF23/FGFR/
KLOTHO signaling, causing phosphate wasting and osteomalacia
[43]. Similarly, another study demonstrates that FGFR signaling
stimulates Fgf23 expression in a dose-dependent manner [44].
These findings suggest that overexpression of FGF2 is a
contributing factor to FGF23 upregulation in our animals.
We found that the use of b-globin promoter leads to an
impressive confinement of FGF2 expression to the marrow. To the
best of our knowledge, we are the first to report that an erythroid
Figure 5. High-level FGF2 induces considerable trabecular
bone formation after nonmyeloablative HSC transplantation
but develops osteomalacia. (a) pQCT analysis of cortical and
trabecular bone mineral density at 11 weeks after transplantation.
Substantial trabecular bone formation was detected. For trabecular
bone, P,0.001. Animals received GFP control or lenti SFFV-FGF2
transduced cells after 3 Gy irradiation. (b) Goldner’s trichrome staining
of a femur from a representative SFFV-FGF2 mouse at 11 weeks after
transplantation. Green colored is mineralized bone. Red colored tissue
indicates unmineralized bone area.
doi:10.1371/journal.pone.0037569.g005
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to the marrow after HSC transplantation. This finding should
have important implications in delivering therapeutic factors to the
marrow for treating hematological diseases such as leukemia.
In the previous study, we found that high-level FGF2 induces
massive trabecular formation [13], which is seemingly inconsistent
with our study with myeloablative transplantation. We reasoned
that the discrepancy might be attributed to the different irradiation
dosage we used: 5 Gy for the earlier study vs. 8 Gy in the majority
of our current study. To test our hypothesis, we provided evidence
that in non-myeloablative transplantation, high-level FGF2 can
induce substantial trabecular bone formation but also induce overt
osteomalacia.
In conclusion, our improved hematopoietic stem cell gene
therapy approach has advanced FGF2-based therapy for bone
regeneration in multiple ways. The use of an erythroid-specific
promoter confines FGF2 expression to the marrow, leading to a
substantial decrease in serum FGF2. Our new strategy not only
promotes massive trabecular bone formation, but also leads to
abrogation of the side effects associated with systemic FGF2
administration such as anemia and osteomalacia. Our improved
therapy represents one step closer to clinical applications in
strengthening the skeleton and battling osteoporosis. At the same
time, we are aware that toxic irradiation used in HSC
transplantation as a preconditioning regimen can not be used in
non-life-threatening diseases like osteoporosis, and we are
addressing this issue by exploiting integrin and SDF-1/CXCR4
signaling pathways (Meng, Baylink, Lau, and Zhang: unpub-
lished).
Materials and Methods
Lentiviral vectors
We used lentiviral vectors to express a modified human FGF2
with a BMP2/4 hybrid secretion signal [45]. In this study, GFP
control vector and 2 FGF2-expressing vectors were used, in which
SFFV, a strong promoter for hematopoietic cells [21,46], and b-
globin promoter, an erythroid-specific promoter of 1.6 kb in
length, were used to drive FGF2 expression [47] (Fig. 1a). For
virus production, a standard calcium phosphate precipitation
method was used. The biological titers of lentiviral vectors were
determined with HT1080 cells (a human fibrosarcoma cell line).
0.1, 0.2 or 0.5 ml concentrated vectors were added into each well
of 12-well plates that were seeded with 5610
4 cells. As a control,
some wells of HT1080 cells were added with Lenti-PGK-GFP-
wpre virus, whose titer was calculated by flow cytometry analysis
of percentage of GFP
+ cells. After 3 days of culture in DMEM/
10% fetal bovine serum (Invitrogen, Grand Island, NY) with
addition of 8 mg/ml protamine sulfate (Sigma-Aldrich Corp,, St.
Louis, MO), cells were harvested for genomic DNA extraction
using the DNeasy kit (Qiagen, Inc., Valencia, CA). To determine
the average copies of integrated lentivirus, real-time PCR was
performed using the SYBRH Green PCR Master Mix (Applied
Biosystems, Foster City, CA) on 7500 Fast Real-Time PCR
System (Applied Biosystems). The titers of non-GFP-expressing
vectors were calculated by normalization with HT1080 cells
transduced with Lenti-PGK-GFP-wpre. After a 1006concentra-
tion, biological titers of more than 5610
7/ml were achieved in our
lab [21,48].
Mice
Six-week old female C57BL/6 mice were purchased from the
Jackson Laboratory (Bar Harbor, ME). All animals were
maintained in the Loma Linda University Animal Facility. All
procedures were conducted under humane conditions and
approved by the Institutional Animal Care and Use Committee
at the Loma Linda University.
Bone marrow Sca-1
+ cells
Whole BM cells were harvested from C57BL/6 mice by
flushing tibiae and femurs with phosphate-buffered saline (PBS)
plus 0.1% bovine serum albumin using a 26G syringe. After
depletion of red blood cells by treatment with RBC lysis buffer,
nucleated cells were enriched for Sca-1
+ cells by MACS using a
Sca-1 Microbead kit from Miltenyi Biotec, Auburn, CA.
Cell transduction
Sca-1
+ cells were plated in non-tissue culture (TC) treated 6-well
plates (Becton Dickinson, Franklin Lakes, NJ) pre-coated with
retronectin (Takara, Otsu, Shiga, Japan) at a density of 2610
6
cells/well. Cells were cultured in Iscove’s modified Dulbecco’s
medium (Invitrogen) containing 10% fetal bovine serum (Invitro-
gen), human TPO (Prospec, East Brunswick, NJ), mouse SCF
(Prospec), human FL (Prospec), human G-CSF (Prospec), and
human IL-3 (Prospec), each at 100 ng/ml. After overnight
prestimulation, concentrated viral stock was added to the cell
culture at a multiplicity of infection of 5. Eight hours later, cells
were harvested and resuspended in PBS for transplantation.
Mouse irradiation and transplantation
Recipient C57BL/6 mice were placed into aerated polystyrene
cubicles and preconditioned by total body irradiation from a
60Co
source (Eldorado model, Atomic Energy of Canada, Ltd.,
Commercial Products Division, Ottawa, Canada) at a single dose
of 8 Gy; dose rate was approximately 0.8 Gy/minute. Two to
three hours after irradiation, transduced 0.5610
6 Sca-1
+ cells were
transplanted into syngeneic C57BL/6 mice via tail vein injection.
To investigate the effects of differential concentrations of FGF2 on
bone formation, SFFV-FGF2 transduced cells were diluted with
un-transduced Sca-1
+ cells by factors of 2, 4 or 8 before
transplantation.
FGF2 expression in Ter119 positive and negative cells
To investigate the specificity of the b-globin promoter, we
harvested BM cells from mice received Lenti b-globin-FGF2
transduced cells at 6 weeks after transplantation. Erythroid cells
were purified by MACS with the use of an Anti-Ter119
Microbead kit (Miltenyi Biotec). Ter119
2 cells were also collected
as a negative control. Protein was extracted from isolated cells
using Qproteome
TM Nuclear Protein kit (Qiagen). FGF2 expres-
sion in Ter119
+ or Ter119
2 cells was determined by ELISA
analysis of protein extracts.
Serum analysis
Mice were sacrificed by CO2 asphyxiation at 6–8 weeks after
transplantation and serum was harvested for a series of analyses.
FGF2 levels were analyzed by ELISA (R&D Systems, Minneap-
olis, MN). Activity of bone formation markers, osteocalcin and
ALP, was measured with osteocalcin ELISA kit (Biomedical
Technologies Inc., MA) and Quantichrom Alkaline Phosphatase
Assay Kit (BioAssay Systems, Hayward, CA), respectively. We also
analyzed indicators of osteomalacia, PTH and FGF23, using PTH
Immunoassay Kit (ALPCO, Salem, NH) and FGF23 ELISA kit
(Immutopics International, San Clemente, CA), respectively.
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Femurs were fixed in 10% formalin for 24 hours and then
stored in PBS containing 0.1% sodium azide at 4uC. Cross-
sectional and volumetric bone parameters (trabecular and cortical
BMD) were measured using an XCT 960M with XCT software
version 5.40 (Roche Diagnostics, Basel, Switzerland) in a multi-
specimen holder designed for the XCT 960M as previously
described [13].
Bone tissue histology
To examine the bone mineralization, femurs were embedded
into methylmethacrylate. A Polycut motorized microtome was
used to cut 5-mM-thick sections; the microsections were stained
with Goldner’s trichrome stain as previously described [49].
Fluorescence-activated cell sorting
Spleen cells were obtained by mincing the spleen. After lysis of
RBC, nucleated cells were washed in PBS and incubated for
30 minutes with phycoerythrin (PE)-conjugated mouse monoclo-
nal antibodies. The antibodies were used to identify cells
expressing CD45R, Gr-1, CD11b, CD3 and Ter119 (eBioscience,
San Diego, CA). Nonspecific staining was excluded using a mouse
isotope immunoglobulin control. 30,000 cells from each sample
were analyzed on a FACSAria II flow cytometer (BD Biosciences,
San Jose, CA).
RT-PCR
Quantitative real-time reverse transcription PCR was per-
formed to determine the gene expression of multiple markers in
whole femurs. After harvesting and cleaning femurs, the samples
were snap frozen in liquid nitrogen. To extract RNAs, the femurs
were pulverized. Total RNA was isolated using TRIzol Reagent
(Invitrogen). First strand cDNA was synthesized using Super-
ScriptH III First-Strand Synthesis System and the OligodT primer
(Invitrogen). Real-time PCR was performed using SYBRH Green
PCR Master Mix (Applied Biosystems) on 7500 Fast Real-Time
PCR System (Applied Biosystems). Gene expression values were
normalized against glyceraldehyde 3-phosphate dehydrogenase
(Gapdh), and relative quantitation of fold change was calculated
using the 2
2DDCT method. Primer sequences for RT-PCR are
listed in Table S1 in Supporting Information S1.
Statistical analysis
Data are presented as mean 6 standard error of the mean
(SEM). Two-tailed Student’s t test was performed. P value of
,0.05 was considered statistically significant.
Supporting Information
Table S1 Primer sequences for real-time RT-PCR.
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